These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20041739)

  • 21. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An embryonic nation.
    Yang X
    Nature; 2004 Mar; 428(6979):210-2. PubMed ID: 15014509
    [No Abstract]   [Full Text] [Related]  

  • 23. Prospects for translational regenerative medicine.
    Chen FM; Zhao YM; Jin Y; Shi S
    Biotechnol Adv; 2012; 30(3):658-72. PubMed ID: 22138411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A crisis in chronic pain care: an ethical analysis. Part three: Toward an integrative, multi-disciplinary pain medicine built around the needs of the patient.
    Giordano J; Schatman ME
    Pain Physician; 2008; 11(6):775-84. PubMed ID: 19057625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The economic value of investing in regenerative medicine.
    Hussain A; Rivers PA
    J Health Care Finance; 2009; 36(2):45-54. PubMed ID: 20499720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The strong financial case for regenerative medicine and the regen industry.
    Mason C; Dunnill P
    Regen Med; 2008 May; 3(3):351-63. PubMed ID: 18462058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Political and medical views on medical marijuana and its future.
    Rubens M
    Soc Work Public Health; 2014; 29(2):121-31. PubMed ID: 24405197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Do we need advice created by political advisors].
    Eckert G
    Klin Monbl Augenheilkd; 2014 Nov; 231(11):1053. PubMed ID: 25574538
    [No Abstract]   [Full Text] [Related]  

  • 29. Manufacturing road map for tissue engineering and regenerative medicine technologies.
    Hunsberger J; Harrysson O; Shirwaiker R; Starly B; Wysk R; Cohen P; Allickson J; Yoo J; Atala A
    Stem Cells Transl Med; 2015 Feb; 4(2):130-5. PubMed ID: 25575525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
    Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global update: Canada.
    Willemse L; Ogbogu U; Johnson S; Rudnicki M
    Regen Med; 2012 Nov; 7(6 Suppl):132-5. PubMed ID: 23210826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value-engineered translation for regenerative medicine: meeting the needs of health systems.
    Bubela T; McCabe C
    Stem Cells Dev; 2013 Dec; 22 Suppl 1(Suppl 1):89-93. PubMed ID: 24304083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stem cells and regenerative medicine on the Asian horizon: an economic, industry and social perspective.
    Sipp D
    Regen Med; 2009 Nov; 4(6):911-8. PubMed ID: 19903008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stem cells and regenerative medicine - future perspectives.
    Brunt KR; Weisel RD; Li RK
    Can J Physiol Pharmacol; 2012 Mar; 90(3):327-35. PubMed ID: 22401558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The challenges of product development and commercialization in a convergence technology world: focus on regenerative medicine.
    Tozer D
    Drug Discov Today; 2010 Aug; 15(15-16):587-9. PubMed ID: 20546921
    [No Abstract]   [Full Text] [Related]  

  • 36. Early evaluation and value-based pricing of regenerative medicine technologies.
    Koerber F; Rolauffs B; Rogowski W
    Regen Med; 2013 Nov; 8(6):747-58. PubMed ID: 24147530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Information Sharing and Investment Performance in the Venture Capital Network Community: An Empirical Study of Environmental-Social-Governance Start-Ups.
    Xue C; Dang X; Shi B; Gu J
    Int J Environ Res Public Health; 2019 Mar; 16(6):. PubMed ID: 30897837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. California: 'the Stem Cell State'. Interview with Jonathan Thomas.
    Thomas J
    Regen Med; 2011 Nov; 6(6 Suppl):113-5. PubMed ID: 21999272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical and organizational way of innovative development of regenerative medicine in security agencies].
    Ryzhman NN; Maksimov AG; Tyrenko VV; Karamullin MA; Yurkin AK; Golota AS; Lisovets DG; Sarana AM; Barsevich OV
    Voen Med Zh; 2015 Mar; 336(3):14-8. PubMed ID: 26454924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regenerative medicine and responsible research and innovation: proposals for a responsible acceleration to the clinic.
    Webster A
    Regen Med; 2017 Oct; 12(7):853-864. PubMed ID: 29094647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.